Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2009-12-15
2011-11-01
Chu, Yong (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S244000
Reexamination Certificate
active
08048902
ABSTRACT:
Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.
REFERENCES:
patent: 6964975 (2005-11-01), Ueno et al.
patent: 7094797 (2006-08-01), Horie et al.
patent: 7135469 (2006-11-01), Pinto
patent: 7229987 (2007-06-01), Ammenn et al.
patent: 7285680 (2007-10-01), Habashita et al.
patent: 7288558 (2007-10-01), Nakade et al.
patent: 7300917 (2007-11-01), Nakade et al.
patent: 2003/0114505 (2003-06-01), Ueno et al.
patent: 2004/0014662 (2004-01-01), Lindquist et al.
patent: 2004/0067908 (2004-04-01), Nakade et al.
patent: 2004/0167132 (2004-08-01), Shankar et al.
patent: 2004/0171037 (2004-09-01), Li et al.
patent: 2004/0171582 (2004-09-01), Nakade et al.
patent: 2004/0192739 (2004-09-01), Solow-Cordero et al.
patent: 2004/0236112 (2004-11-01), Singh et al.
patent: 2004/0266840 (2004-12-01), Singh et al.
patent: 2005/0065194 (2005-03-01), Shankar et al.
patent: 2005/0101518 (2005-05-01), Solow-Cordero
patent: 2005/0113283 (2005-05-01), Solow-Cordero et al.
patent: 2005/0261298 (2005-11-01), Solow-Cordero et al.
patent: 2006/0135577 (2006-06-01), Nakade et al.
patent: 2006/0148830 (2006-07-01), Terakado et al.
patent: 2006/0194850 (2006-08-01), Yamamoto et al.
patent: 2008/0051372 (2008-02-01), Chun
patent: 2008/0064731 (2008-03-01), Nakade et al.
patent: 2008/0234230 (2008-09-01), Nakade et al.
patent: 2008/0293764 (2008-11-01), Mashiko et al.
patent: 2010/0311799 (2010-12-01), Hutchinson et al.
patent: 2011/0082164 (2011-04-01), Ryan et al.
patent: 2011/0082181 (2011-04-01), Seiders et al.
patent: 0702012 (1996-03-01), None
patent: 1258484 (2002-11-01), None
patent: 1550461 (2005-07-01), None
patent: 2466121 (2010-12-01), None
patent: 11-240873 (1999-09-01), None
patent: 2006-096712 (2006-04-01), None
patent: WO-01-60819 (2001-08-01), None
patent: WO-02-00651 (2002-01-01), None
patent: WO-00-59902 (2002-10-01), None
patent: WO-02-085290 (2002-10-01), None
patent: WO-03-062392 (2003-07-01), None
patent: WO-03-097047 (2003-11-01), None
patent: WO-2004-031118 (2004-04-01), None
patent: WO-2005-012269 (2005-02-01), None
patent: WO-2005-066138 (2005-07-01), None
patent: WO-2006-131336 (2006-12-01), None
patent: WO-2007-007588 (2007-01-01), None
patent: WO-2007-024922 (2007-03-01), None
patent: WO-2007-096647 (2007-08-01), None
patent: WO-2007-139946 (2007-12-01), None
patent: WO-2008-024979 (2008-02-01), None
patent: WO-98-28282 (2008-07-01), None
patent: WO-2008-112201 (2008-09-01), None
patent: WO-2009-0011850 (2009-01-01), None
patent: WO-2009-135590 (2009-11-01), None
patent: WO-2010-068775 (2010-06-01), None
patent: WO-2010-068775 (2010-06-01), None
patent: WO-2010-077882 (2010-07-01), None
patent: WO-2010-077883 (2010-07-01), None
patent: WO-2010-141761 (2010-12-01), None
patent: WO-2010-141768 (2010-12-01), None
patent: WO-2011-017350 (2011-02-01), None
patent: WO-2011-041461 (2011-04-01), None
patent: WO-2011-041462 (2011-04-01), None
patent: WO-2011-041694 (2011-04-01), None
patent: WO-2011-041729 (2011-04-01), None
Anliker et al., “Cell surface receptors in lysophospholipid signaling,” Seminars Cell Develop Biol 15:457-465 (2004).
Castelino et al., “Genetic deletion or pharmacologic antagonism of LPA1ameliorates dermal fibrosis in a mouse model of systemic sclerosis,” 11thInternational Workshop on Scleroderma Research, Abstracts, Aug. 1-4, 2010, Boston, MA, p. S-57.
Choi et al., “Biological roles of lysophospholipid receptors revealed by genetic null mice: An update,” Biochim Biophys Acta 1781:531-539 (2008).
Chun and Rosen, “Lysophospholipid Receptrs as Potential Drug Targets in Tissue Transplantation and Autoimmune Diseases,” Curr Pharma Design 12:161-171 (2006).
Chun, “Lysophospholipids in the nervous system,” Prostaglandins & other Lipid Mediators 77:46-51 (2005).
Fukushima et al., “The LPA Receptors,” Prostaglandins & other Lipid Mediators 64:21-32 (2001).
Gardell et al., “Emerging medicinal roles for lysophospholipid signaling,” Trends in Mol Med 12(2):65-75 (2006).
Ishii et al., “Lysophospholipid Receptors: Signaling and Biology,” Annu Rev Biochem 73:321-354 (2004).
Ley and Zarbock, “From lung injury to fibrosis,” Nature Medicine 14(1):20-21 (2008).
Mills and Moolenaar, “The Emerging Role of Lysophosphatidic Acid in Cancer,” Nature Reviews/Cancer 3:582-591 (2003).
Murph et al., “Sharpening the edges of understanding the structure/function of the LPA1 receptor: Expression in cancer and mechanisms of recognition,” Biochim Biophys Acta 1781:547-557 (2008).
Ohta et al., “Ki16425, a Subtype-Selective Antagonist for EDG-Family Lysophosphatidic Acid Receptors,” Mol Pharma 64(4):994-1005 (2003).
Parrill et al., “Sphingosine 1-phosphate and lysophosphatidic acid receptors: agonist and antagonist binding and progress toward development of receptor-specific ligands,” Seminars Cell Develop Biol 15:467-476 (2004).
Pradere et al., “Lysophosphatidic acid and renal fibrosis,” Biochim Biophys Acta (2008) doi:10.1016/j.bbalip.2008.04.001.
Pradere et al., “LPA1Receptor Activation Promotes Renal Insterstitial Fibrosis,” J Am Soc Nephrol 18:3110-3118 (2007).
Prestwich et al., “New metabolically stabilized analogues of lysophosphatidic acid: agonists, antagonists and enzyme inhibitors,” Biochem Society Transactions 33(6):1357-1361 (2005).
Sardar et al., “Molecular basis for lysophoshatidic acid receptor antagonist selectivity,” Biochim Biophys Acta 1582:309-317 (2002).
Scott, “Lysophosphatidic acid is an important mediator of fibroblast recruitment in IPF,” Thorax 63:654 (2008).
Swaney et al., “Pharmacokinetic and Pharmacodynamic Characterization of an Oral, LPA1-selective Antagonist,” Journal of Pharmacology and Experimental Therapeutics , published Dec. 15, 2010 as DOI:10.1124/jpet.110.175901.
Swaney et al., “A novel, orally activa LPA1receptor antagonist inhibits lung fibrosis in the mouse bleomycin model,” British J Pharmacol. 160:1699-1713 (2010).
Tager et al., “The Lysophosphatidic Acid Receptor LPA1Links Pulmonary Fibrosis to Lung Injury by Mediating Fibroblast Recruitment and Vascular Leak,” Nature Medicine 14(1):45-54 (2008).
Toews et al., “Lysophosatidic acid in airway function and disease,” Biochim Biophys Acta 1582:240-250 (2002).
Watanabe et al., “Plasma lysophosphatidic acid level and serum autotaxin activity are increased in liver injury in rats in relation to its severity,” Life Sciences 81:1009-1015 (2007).
Watanabe et al., “Both Plasma Lysophosphatidic Acid and Serum Autotaxin Levels are Increased in Chronic Hepatitis C,” J. Clin. Gastroenterol. 41(6):616-623 (2007).
Watterson et al., “Regulation of fibroblast functions by lysophospholipid mediators: Potential roles in wound healing,” Wound Rep Reg 15:607-616 (2007).
Yamamoto et al., “Synthesis and evaluation of isoxazole derivatives as lysophosphatidic acid (LPA) antagonists,” Bioorg. Med. Chem. Ltrs. 17(13):3736-3740 (2007).
Yang et al., “G protein-coupled lysophosphatidic acid receptors stimulate proliferation of colon cancer cells through the β-catenin pathway,” PNAS 102(17):6027-6032 (2005).
Yang et al., “In vivo roles of lysophospholipid receptors revealed by gene targeting studies in mice,” Biochim Biophys Acta 1582:197-203 (2002).
Yokoyama et al., “Stereochemical properties of lysophosphatidic acid receptor activation and metabolism,” Biochim Biophys Acta 1582:295-308 (2002).
Zhao and Natarajin, “Lysophosphatidic acid signaling in airway epithelium: Role in airway inflammation and remodeling,”
Arruda Jeannie M.
Hutchinson John Howard
Parr Timothy
Roppe Jeffrey Roger
Seiders Thomas Jon
Amira Pharmaceuticals, Inc.
Chu Yong
Wilson Sonsini Goodrich & Rosati
LandOfFree
Antagonists of lysophosphatidic acid receptors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antagonists of lysophosphatidic acid receptors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antagonists of lysophosphatidic acid receptors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4278436